Patents Issued in July 6, 2021
-
Patent number: 11052136Abstract: The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.Type: GrantFiled: March 14, 2017Date of Patent: July 6, 2021Assignee: FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAUInventors: Lina Badimon Maestro, Judit Cubedo Ràfols, Gemma Vilahur Garcia, Teresa Padró Capmany
-
Patent number: 11052137Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: GrantFiled: October 24, 2018Date of Patent: July 6, 2021Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITES LEUVEN, K.U. LEUVEN R&DInventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
-
Patent number: 11052138Abstract: A nucleic acid encoding a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) operatively linked to a signaling domain that polarizes a macrophage to an M1 macrophage; wherein the nucleic acid is operatively linked to a macrophage specific promoter; and wherein the scFv is specific for a human antigen. Monocytes or macrophages comprising such a nucleic acid.Type: GrantFiled: September 5, 2018Date of Patent: July 6, 2021Assignee: Thunder Biotech Inc.Inventors: Kim Leslie O'Neill, Scott Weber
-
Patent number: 11052139Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.Type: GrantFiled: September 28, 2017Date of Patent: July 6, 2021Assignee: Bavarian Nordic A/SInventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
-
Patent number: 11052140Abstract: What is described is a method of treatment of a patient with a tumor, comprising administering a cell responsive to a peptide comprising a tumor epitope, wherein the tumor epitope comprises an amino acid substitution in a tumor antigen. The tumor antigen is preferably selected from the group consisting of NYESO-I157-165, NYESO-II157-170, or MART-126-35, preferably SEQ ID NOS: 1-351, 361-376, and 392-401.Type: GrantFiled: June 24, 2019Date of Patent: July 6, 2021Inventors: Cassian Yee, Yongqing Li, C. Siddiq Abdul-Alim
-
Patent number: 11052141Abstract: Methods of mitigating the risk of rejection of an allograft or xenograft in an incompatible recipient by neutralizing one or more populations of circulating antibody cross-reactive with a carbohydrate antigen expressed by the allograft or xenograft. The method includes administering to the recipient by intravenous infusion a concentration of a synthetic antigen lipid construct sufficient to neutralize the one or more populations of circulating antibody in the recipient.Type: GrantFiled: November 9, 2018Date of Patent: July 6, 2021Assignee: KODE BIOTECH LIMITEDInventors: Stephen Micheal Henry, Caroline Ann Oliver
-
Patent number: 11052142Abstract: For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively. The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.Type: GrantFiled: March 9, 2017Date of Patent: July 6, 2021Inventors: Petr Gennadievich Aparin, Vyacheslav Leonidovich Lvov, Stanislava Ivanovna Elkina, Marina Eduardovna Golovina
-
Patent number: 11052143Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.Type: GrantFiled: January 27, 2020Date of Patent: July 6, 2021Assignee: SCANDINAVIAN BIOPHARMA HOLDING ABInventors: Ann-Mari Svennerholm, Joshua Tobias, Nils Carlin, Jan Holmgren
-
Patent number: 11052144Abstract: A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.Type: GrantFiled: April 24, 2020Date of Patent: July 6, 2021Assignee: DCPRIME B.V.Inventors: Erik Hans Manting, Satwinder Kaur Singh, Vinod Sommandas
-
Patent number: 11052145Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.Type: GrantFiled: May 29, 2020Date of Patent: July 6, 2021Assignee: Evaxion Biotech A/SInventors: Niels Iversen Møller, Andreas Holm Mattsson
-
Patent number: 11052146Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: June 15, 2018Date of Patent: July 6, 2021Assignee: Novavax, Inc.Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 11052147Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.Type: GrantFiled: May 15, 2018Date of Patent: July 6, 2021Inventors: Ahmad Shakeb Sediq, Wouter Frank Tonnis, Martinus Anne Hobbe Capelle
-
Patent number: 11052148Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.Type: GrantFiled: May 30, 2017Date of Patent: July 6, 2021Assignees: Geo Vax, Inc., The Georgia State University Research FoundationInventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
-
Patent number: 11052149Abstract: The present invention provides a composition comprising a) a polyacetal polymer, a polyester polymer and/or a biodegradable polymer; b) a cyclic dinucleotide; and c) an antigen and/or an antibody, as well as methods of using same.Type: GrantFiled: September 19, 2017Date of Patent: July 6, 2021Assignee: The University of North Carolina at Chapel HillInventors: Jenny P.-Y. Ting, Robert Junkins, Brandon Johnson, Kristy Ainslie, Eric Bachelder, Matthew Gallovic, Michael Collier, Ning Cheng
-
Patent number: 11052150Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.Type: GrantFiled: April 12, 2018Date of Patent: July 6, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Nobuyuki Yasuda, Kiyoshi Oketani, Hiroko Baba, Tomohisa Nakano, Masahiko Mori
-
Patent number: 11052151Abstract: Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.Type: GrantFiled: November 16, 2018Date of Patent: July 6, 2021Assignee: California Institute of TechnologyInventors: Elaine Hsiao, Sarkis K. Mazmanian, Paul H. Patterson, Sara McBride
-
Patent number: 11052152Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.Type: GrantFiled: September 23, 2020Date of Patent: July 6, 2021Assignee: DYVE BIOSCIENCES, INC.Inventors: Bruce J. Sand, Ryan R. Beal, Philippe H. Burnham
-
Patent number: 11052153Abstract: Compositions including a highly branched alpha-D-glucan or modified forms thereof and a solute compound are described herein. The compositions can provide increased water solubility and/or increased rate of dissolution for the solute compound. The compositions can also provide increased stability for the solute compound. Methods for preparing and using compositions including a solute compound and a highly branched alpha-D-glucan are also described.Type: GrantFiled: October 8, 2018Date of Patent: July 6, 2021Assignee: Purdue Research FoundationInventors: Yuan Yao, Jingmin Joanne Zhang
-
Patent number: 11052154Abstract: A Ras protein degradation inducing molecule that can induce degradation of Ras proteins, and a pharmaceutical composition that contains this Ras protein degradation inducing molecule are provided. The Ras protein degradation inducing molecule is a conjugate of a Ras protein affinity molecule which has affinity to Ras proteins, and a proteolysis-inducing tag which has affinity to protease and does not inhibit proteolysis of proteins by the protease.Type: GrantFiled: November 13, 2017Date of Patent: July 6, 2021Assignee: Tokyo University of Science FoundationInventors: Etsuko Miyamoto, Masaaki Ozawa
-
Patent number: 11052155Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.Type: GrantFiled: March 17, 2017Date of Patent: July 6, 2021Assignee: SYNTARGA BVInventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
-
Patent number: 11052156Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.Type: GrantFiled: November 14, 2019Date of Patent: July 6, 2021Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Serengulam V. Govindan
-
Patent number: 11052157Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.Type: GrantFiled: March 22, 2019Date of Patent: July 6, 2021Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD.Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
-
Patent number: 11052158Abstract: Provided are liposome constructs for delivery of urea to the vitreoretinal interface of the eye. The liposome constructs are agglomerates of small lamellar vesicles (SUVs) and have a greater density than the vitreal fluid, such that they sink to the back of the eye rather than dispersing throughout the vitreous.Type: GrantFiled: August 18, 2017Date of Patent: July 6, 2021Inventor: Troy Bremer
-
Patent number: 11052159Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: November 16, 2020Date of Patent: July 6, 2021Assignee: TRANSLATE BIO, INC.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 11052160Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion DA and DB).Type: GrantFiled: January 31, 2019Date of Patent: July 6, 2021Assignee: Avelas Biosciences, Inc.Inventors: Jesus Gonzalez, Junjie Liu
-
Patent number: 11052161Abstract: Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.Type: GrantFiled: August 27, 2018Date of Patent: July 6, 2021Assignee: Duke UniversityInventors: Matthew S. Freeman, Bastiaan Driehuys
-
Patent number: 11052162Abstract: The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.Type: GrantFiled: September 15, 2017Date of Patent: July 6, 2021Assignee: TEXAS CHILDREN'S HOSPITALInventors: Ananth Annapragada, Anil Shetty, Ketankumar B Ghaghada, Eric Tanifum
-
Patent number: 11052163Abstract: The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.Type: GrantFiled: September 21, 2017Date of Patent: July 6, 2021Assignee: Washington UniversityInventors: Gregory M. Lanza, Samuel I. Achilefu, Grace Hufang Cui
-
Patent number: 11052164Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.Type: GrantFiled: September 26, 2019Date of Patent: July 6, 2021Assignee: Biosphere Medical, Inc.Inventors: Philippe Reb, Celine Chaix
-
Patent number: 11052165Abstract: The invention discloses a method for virus clearance of a cell culture medium, comprising the steps of: i) providing a bulk medium portion, comprising amino acids and glucose, and a first additive portion, comprising vitamins in aqueous solution; ii) subjecting the bulk medium portion to a high temperature short time treatment (HTST); iii) passing the first additive portion through a virus retentive filter or an ultrafilter; and iv) after steps ii) and iii), mixing the bulk medium portion with the first additive portion to obtain a cell culture medium.Type: GrantFiled: September 28, 2017Date of Patent: July 6, 2021Assignee: Global Life Sciences Solutions USA LLCInventors: Andreas Castan, Colin R. Tuohey
-
Patent number: 11052166Abstract: An apparatus is provided for delivering IR and/or UV radiation, to an area or a surface in which virions, such as SARS-CoV-2 (the virus that causes the disease, COVID-19), may exist, wherein the IR radiation is intended to degrade the viral envelope of the virions and wherein the UV radiation is intended to break specific molecular bonds in order to degrade the RNA of the virion contained within a viral envelope.Type: GrantFiled: July 13, 2020Date of Patent: July 6, 2021Inventors: James Arthur Graham, Jr., Ghobad Heidari-Bateni, Stanton C Braden, Craig Martin Gregersen
-
Patent number: 11052167Abstract: A glass aroma diffuser is provided, including a base, a water tank and a top cover. The bottom of the water tank is fixed on the base, the opening of the water tank is upward, and the bottom of the water tank is provided with an atomizer, and the water tank is configured to carry the liquid to be atomized; the top cover is provided with an exhaust nozzle for discharging mist. The top cover and the water tank of the aroma diffuser of the present disclosure are made of glass material, the atomizer is arranged under the water tank, and the exhaust nozzle is arranged on the top cover, which greatly reduces the use of plastic materials, thus reducing the plastic taste carried in the mist, reducing the probability of mist affecting human health, greatly improving the use experience, and making users feel more comfortable to use.Type: GrantFiled: August 25, 2020Date of Patent: July 6, 2021Inventor: Wen Wang
-
Patent number: 11052168Abstract: An air germicidal treatment device and system for removing or eliminating unwanted pathogens or bacteria in an airstream is shown. The device or system has a removable irradiation chamber that divides an interior area of the device into an air pre-chamber area, an air post-chamber area and an irradiation area therebetween. The removable irradiation chamber is generally trapezoidal in shape and has end walls that are inclined with respect to an interior divider wall.Type: GrantFiled: November 15, 2017Date of Patent: July 6, 2021Assignee: AEROBIOTIX, INC.Inventor: David Louis Kirschman
-
Patent number: 11052169Abstract: Systems, apparatus and methods for disinfection of airflow. An apparatus for disinfecting air-conditioned airflow in a confined space includes: a modular housing; and a disinfection chamber enclosed within the housing. The disinfection chamber includes a plurality of disinfection sheets. Each disinfection sheet comprises a plurality of ultraviolet (UV) light sources. The airflow is configured to be routed along a serpentine pathway within the housing to expose microorganisms in the airflow to far UV-C light emitted by the UV light sources for an extended and optimal duration.Type: GrantFiled: August 6, 2020Date of Patent: July 6, 2021Assignee: Perumala Holdings, LLCInventor: Madhavan Pisharodi
-
Patent number: 11052170Abstract: The invention relates to a device for treating blood flow in an internal wound, including a handling member connected to a series of successively narrower tubes, each tube including a liquid-expandable article. The tubes can be pivotably connected to each other, allowing the tubes to conform to the contours of the wound, or fixed together. The tubes can be encased in a liquid-soluble layer that keeps the liquid-expandable article sequestered from liquids. The stepwise-tapering profile of the device allows for its insertion into the internal wound with little or no resistance until fully seated. Upon encountering liquids within the wound, the liquid-soluble layer can dissolve to expose the liquid-expandable article. When exposed to the wound liquids, the liquid-expandable element can expand in volume, providing compressive pressure against internal wound surfaces and minimizing blood loss. The tubes and the liquid-expandable element can include therapeutic agents for treating the wound.Type: GrantFiled: February 22, 2019Date of Patent: July 6, 2021Assignee: QTF INNOVATION LLCInventors: Andrew Studdert, Michael R. Miller
-
Patent number: 11052171Abstract: A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative.Type: GrantFiled: April 26, 2019Date of Patent: July 6, 2021Assignee: NATIONAL INSTITUE FOR MATERIALS SCIENCEInventor: Tetsushi Taguchi
-
Patent number: 11052172Abstract: The invention relates to a kit to prepare an hemostatic flowable comprising: —A hemostatic powder having a composition comprising: ?non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; ?at least one monosaccharide; and ?at least one glycosaminoglycan; —A saline solution to be mixed with the hemostatic powder in order to form the hemostatic flowable. The invention also relates to a method for preparing an hemostatic flowable with such a kit, comprising the steps of: a. Providing the hemostatic powder in a container; b. Adding a quantity of the saline solution in the container enclosing the hemostatic powder, closing and shaking said container in order to promote hydration of the hemostatic powder to form the hemostatic flowable.Type: GrantFiled: August 11, 2017Date of Patent: July 6, 2021Assignee: BIOM'UP FRANCE SASInventors: William Spotnitz, Valérie Centis, Doris Moura Campos, Alexia De Gasperis
-
Patent number: 11052173Abstract: The present disclosure relates to a biocompatible, electrically conductive polymer capable of carrying the electrical potential of a cardiac impulse. The present disclosure also relates to treatments using the electrically conductive polymer, such as for atrial fibrillation.Type: GrantFiled: May 22, 2019Date of Patent: July 6, 2021Assignee: University Health NetworkInventor: Ren-Ke Li
-
Patent number: 11052174Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.Type: GrantFiled: March 14, 2017Date of Patent: July 6, 2021Assignees: Mochida Pharmaceutical Co., Ltd.Inventors: Yoshihisa Suzuki, Masao Tanihara, Mitsuko Isaji
-
Patent number: 11052175Abstract: Cartilage fibers and implants made therefrom are disclosed, with and without cartilage particles. Methods for making the cartilage fibers and the implants containing them are also disclosed. The implants may be pre-shaped and may be reshapable and provide good shape retention and little swelling when placed into a cartilage defect.Type: GrantFiled: August 15, 2016Date of Patent: July 6, 2021Assignee: Musculoskeletal Transplant FoundationInventors: Michael A. Nasert, Florence Stoffel, Paul R. Williams, Alex Callahan
-
Patent number: 11052176Abstract: A two-layer gradient coating article is provided that is operable to cause selective adhesion and directional migration of endothelial cells. The first layer includes cell-resisting polymers that repels cells, the second layer includes one layer of peptides that has affinity to and binds specifically to endothelial cells. Furthermore, the peptides are distributed in a gradient, in which attached ECs migrate towards the direction of increased concentration, thus enriching the ECs to a desired locus. The combination of a cell-repelling layer and a graded affinity peptide produces a unique result of selective adhesion, directional migration, thus local enrichment of endothelial cells. A method for using such gradient coating article and its potential use in treating cardiovascular diseases are also provided. The invention provides an inexpensive, stable and effective means for attracting ECs to desirable locations.Type: GrantFiled: October 10, 2017Date of Patent: July 6, 2021Assignee: ZHEJIANG UNIVERSITYInventors: Changyou Gao, Shan Yu, Zhengwei Mao
-
Patent number: 11052177Abstract: The invention provides compositions comprising a plurality of polymer layers for preventing or inhibiting microbial infections. Specifically, the invention provides a combination of a cationic polymer layer that resists adhesion of a microbe to its surface and an anionic polymer layer that releases a cationic anti-microbial agent in response to a change in pH or electrostatic balance.Type: GrantFiled: September 8, 2014Date of Patent: July 6, 2021Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hyun-Su Lee, David M. Eckmann, Russell Composto
-
Patent number: 11052178Abstract: Vacuum pump (18) for a medical aspirator (10), the pump (18) comprising a tubular member (20); a piston (22) slidably arranged within the tubular member (20); a piston rod (24) connected to the piston (22); and a coupling mechanism (36) for detachably and functionally connecting the piston rod (24) to a motor (38) for driving the pump (18), wherein the piston rod (24) is configured to reciprocate linearly during operation of the pump (18).Type: GrantFiled: September 10, 2015Date of Patent: July 6, 2021Assignee: EXCITUS ASInventors: Øyvind Tjølsen, Terje Bondhus, Per Reidar Ørke
-
Patent number: 11052179Abstract: A novel artificial circulatory assistance chamber for various uses associated with cardiovascular procedures, having a rigid capsule with a base and a dome, with blood inlet connectors and blood outlet connectors, and respective one-way valves. The rigid capsule contains an impermeable membrane that divides the capsule into a blood compartment and an outer compressible compartment that is filled with a volume of gas/liquid.Type: GrantFiled: May 26, 2014Date of Patent: July 6, 2021Assignee: ZAMMI INSTRUMENTAL LTDAInventor: Luiz Henrique Vargas Fonseca
-
Patent number: 11052180Abstract: A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber.Type: GrantFiled: March 30, 2015Date of Patent: July 6, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael E. Hogard, Donald D. Busby, Robert W. Childers, Yuanpang Samuel Ding, Katherine M. Holian, Mark E. Jablonski, Thomas D. Kelly, Shincy J. Maliekkal, Rodolfo G. Roger, Donald A. Smith, Atif M. Yardimci, Ying-Cheng Lo
-
Patent number: 11052181Abstract: A cassette integrated system. The cassette integrated system includes a mixing cassette, a balancing cassette, a middle cassette fluidly connected to the mixing cassette and the balancing cassette and at least one pod. The mixing cassette is fluidly connected to the middle cassette by at least one fluid line and the middle cassette is fluidly connected to the balancing cassette by at least one fluid line. The at least one pod is connected to at least two of the cassettes wherein the pod is located in an area between the cassettes.Type: GrantFiled: October 9, 2020Date of Patent: July 6, 2021Assignee: DEKA Products Limited PartnershipInventors: Michael J. Wilt, Kevin L. Grant, James D. Dale, Jason A. Demers, Brian D. Tracey
-
Patent number: 11052182Abstract: The present invention relates to a method for checking a dialyzer for the presence of a leak in the semipermeable membrane of the dialyzer, wherein the membrane divides the inner dialyzer space into a least one blood chamber and into at least one dialyzate chamber, wherein the blood chamber is flowed through by blood in the operation of the dialyzer and is in fluid communication with a blood-side line system and the vascular system of the patient, and wherein the dialyzate chamber is flowed through by dialysis fluid in the operation of the dialyzer and is in fluid communication with a dialyzate-side line system, wherein the method comprises the following steps: a) emptying the blood chamber or the dialyzate chamber of blood and of dialysis fluid respectively and keeping the fluid (blood or dialyzate) in the non-emptied dialyzate chamber or blood chamber; b) building up a test pressure by means of a gas, in particular by means of air, in the emptied blood chamber or in the emptied dialyzate chamber; and c)Type: GrantFiled: December 23, 2016Date of Patent: July 6, 2021Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBHInventors: Reiner Spickermann, Gerhard Wiesen
-
Patent number: 11052183Abstract: The present disclosure provides devices and methods of using same for cleansing a solution (e.g., a salt or used dialysis solution) of urea via electrooxidation, and more specifically to cleansing a renal therapy solution/dialysis solution of urea via electrooxidation so that the renal therapy solution/dialysis solution can be used or reused for treatment of a patient. In an embodiment, a device for the removal of urea from a fluid having urea to produce a cleansed fluid includes a urea decomposition unit and an electrodialysis unit.Type: GrantFiled: August 26, 2019Date of Patent: July 6, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Yuanpang Samuel Ding, Cristian Adolfo Menzel Bueno, Rosa Yeh
-
Patent number: 11052184Abstract: A membrane separation device is disclosed along with systems and methods employing the device in blood processing procedures. In one embodiment, a spinning membrane separator is provided in which at least two zones or regions are created in the gap between the spinning membrane and the shell, such that mixing of the fluid between the two regions is inhibited by a radial rib or ridge associated with the spinning membrane that decreases the gap between the spinning membrane and the shell to define two fluid regions, the ridge isolating the fluid in the two regions to minimize mixing between the two. Automated systems and methods are disclosed for separating a unit of previously-collected whole blood into selected blood components, such as concentrated red cells and plasma, for collecting red cells and plasma directly from a donor in a single pass, and for cell washing. Data management systems and methods and priming methods are also disclosed.Type: GrantFiled: December 13, 2018Date of Patent: July 6, 2021Assignee: Fenwal, Inc.Inventors: Benjamin Kusters, Kyungyoon Min, Christopher Wegener
-
Patent number: 11052185Abstract: The present invention concerns a medical injection device for apportioning set doses of a preservative containing liquid drug. The injection device comprises a housing supporting a cartridge containing the preservative containing liquid drug and a needle cannula for transferring the liquid drug from the cartridge and through the skin of a user. Further, a needle shield which is axially movable in relation to the housing is also present. The axially movable shield carries a cleaning reservoir for cleaning at least the tip of the needle cannula between subsequent injections and the cleaning reservoir is preferably filled with preservative containing liquid drug directly from the cartridge upon initiation of the injection device. In order to eliminate any overpressure being built up inside the cleaning reservoir during the filling process, the cleaning reservoir is provided with an outlet configured to be permanently sealed by a user activated operation.Type: GrantFiled: September 19, 2016Date of Patent: July 6, 2021Assignee: Novo Nordisk A/SInventors: Bjoern Gullak Larsen, Christian Plambech, Lars Eilertsen, Mattias Ingerslev, Ruben Archilla, Soeren Dyring Jensen